Volition Shows Nu.Q H3K27Me3 Blood Test Predicts NSCLC Outcomes
Volition presented data in Copenhagen showing its Nu.Q Cancer assay measures preoperative H3K27Me3-nucleosome levels to stratify non small cell lung cancer patients by survival outcomes. High levels predicted poorer survival, low levels better prognosis, and the test may detect micro-metastases and inform systemic treatment decisions.
1. Abstract Presentation at ELCC
Volition presented an abstract at the European Lung Cancer Conference in Copenhagen, outlining the use of its Nu.Q Cancer assays to measure preoperative H3K27Me3-nucleosome levels in non small cell lung cancer patients.
2. Prognostic Biomarker Findings
The study found that high H3K27Me3-nucleosome levels were associated with poorer recurrence-free and overall survival, while low levels correlated with improved outcomes, suggesting the test can stratify patient risk.
3. Clinical and Commercial Implications
The ability to detect micro-metastatic disease and guide systemic treatment decisions positions Nu.Q H3K27Me3 as a potential tool for personalized lung cancer management and marks a step towards its first clinical use.